Equity Overview
Price & Market Data
Price: $1.60
Daily Change: +$0.10 / 6.25%
Daily Range: $1.60 - $1.60
Market Cap: $1,161,806,208
Daily Volume: 8,800
Performance Metrics
1 Week: 6.67%
1 Month: -13.51%
3 Months: -3.03%
6 Months: 23.08%
1 Year: 82.86%
YTD: -13.51%
Details
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.